Search research articles
Contact Us
Filters
Showing results (61-70 of 164) with videos related to
Page
of 17
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 3, 2012
Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors
Aung Naing, Patricia LoRusso, Siqing Fu, et al.
Plos One
|
November 17, 2018
Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer
Z Ping Lin, Yong-Lian Zhu, Ying-Chun Lo, et al.
Cancer Chemotherapy and Pharmacology
|
August 11, 2016
Lack of pharmacokinetic drug-drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors
Ding Wang, Fadi Braiteh, James J Lee, et al.
Cancer Chemotherapy and Pharmacology
|
September 24, 2013
Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528
Shirish M Gadgeel, Danika L Lew, Timothy W Synold, et al.
Investigational New Drugs
|
June 25, 2008
Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors
Patricia Lorusso, Elisabeth I Heath, Jesse McGreivy, et al.
Cancer
|
May 12, 2005
A phase II study of bortezomib in the treatment of metastatic malignant melanoma
Svetomir N Markovic, Susan M Geyer, Fitzroy Dawkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 9, 2013
Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors
Cristiana Sessa, Patricia Lorusso, Anthony Tolcher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 5, 2002
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition
Joan Albanell, Federico Rojo, Steve Averbuch, et al.
Cancer Chemotherapy and Pharmacology
|
October 1, 2015
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors
Anthony W Tolcher, Patricia LoRusso, Jennifer Arzt, et al.
Journal of Clinical Pharmacology
|
November 5, 2002
Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases
Tianling Chen, James Berenson, Robert Vescio, et al.
Page
of 17
Search research articles
Search
Showing results (61-70 of 164) with videos related to
Sort By:
Page
of 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 3, 2012
Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors
Aung Naing, Patricia LoRusso, Siqing Fu, et al.
Plos One
|
November 17, 2018
Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer
Z Ping Lin, Yong-Lian Zhu, Ying-Chun Lo, et al.
Cancer Chemotherapy and Pharmacology
|
August 11, 2016
Lack of pharmacokinetic drug-drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors
Ding Wang, Fadi Braiteh, James J Lee, et al.
Cancer Chemotherapy and Pharmacology
|
September 24, 2013
Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528
Shirish M Gadgeel, Danika L Lew, Timothy W Synold, et al.
Investigational New Drugs
|
June 25, 2008
Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors
Patricia Lorusso, Elisabeth I Heath, Jesse McGreivy, et al.
Cancer
|
May 12, 2005
A phase II study of bortezomib in the treatment of metastatic malignant melanoma
Svetomir N Markovic, Susan M Geyer, Fitzroy Dawkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 9, 2013
Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors
Cristiana Sessa, Patricia Lorusso, Anthony Tolcher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 5, 2002
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition
Joan Albanell, Federico Rojo, Steve Averbuch, et al.
Cancer Chemotherapy and Pharmacology
|
October 1, 2015
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors
Anthony W Tolcher, Patricia LoRusso, Jennifer Arzt, et al.
Journal of Clinical Pharmacology
|
November 5, 2002
Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases
Tianling Chen, James Berenson, Robert Vescio, et al.
Page
of 17